The study utilized a double-blind, placebo-controlled, crossover design to examine the effects of psilocybin (25 mg) in healthy subjects after pretreatment with either escitalopram or placebo. Escitalopram was administered at 10 mg daily for 7 days, followed by 20 mg daily for another 7 days, including the day of psilocybin administration. The study aimed to determine whether escitalopram pretreatment would alter the acute subjective and adverse effects of psilocybin.
Key findings include:
- Escitalopram pretreatment did not affect the positive mood effects of psilocybin but significantly reduced bad drug effects, anxiety, adverse cardiovascular effects, and other adverse effects compared to placebo pretreatment.
- No significant changes were observed in the pharmacokinetics of psilocin, the active metabolite of psilocybin, indicating that escitalopram does not alter how psilocybin is metabolized in the body.
- Escitalopram did not affect the expression of HTR2A or SCL6A4 genes, which encode the 5-HT2A receptor and serotonin transporter, respectively, suggesting that the mechanism of action of psilocybin remains unchanged.
- The study concluded that escitalopram and psilocybin can be safely co-administered, potentially allowing patients to continue their antidepressant treatment without the need for a washout period before psilocybin therapy.
This research provides valuable insights into the interaction between antidepressants and psychedelics, suggesting that escitalopram pretreatment could mitigate the adverse effects of psilocybin without compromising its therapeutic benefits. Further studies are recommended to explore these interactions in patients with psychiatric disorders and over longer pretreatment periods.
